Brits desperately searching for Ozempic

Google searches for Ozempic are up a staggering 865% in recent days after latest research in Europe espoused a multitude of health benefits.

Research conducted by the European Congress of Obesity (ECO) last week, on 14 May, claimed that GLP-1 weight loss drugs such as Ozempic and Wegovy may reduce the risk of heart attack, stroke and death by cardiovascular disease by some 20%.

Since then, interest in the drugs has evidently spiked in the UK, with Google searches including queries over eligibility and the cost of the treatments.

“Many individuals in the UK have been exploring whether they qualify for these treatments,” said Addy Mohammad, chief executive of Simple Online Pharmacy, which describes itself as ‘one of the world’s leading providers of weight loss medication, having dispensed to some 120,000 British patients

“This trend is primarily driven by the aim to reduce body weight, yet recent studies suggest there might be additional advantages associated with these treatments beyond mere weight management.”

The success of Ozempic and Wegovy has been the driving force behind Novo Nordisk’s soaring valuation.

Novo Nordisk shares are up 400% in recent years, and it is now Europe’s most valuable company at around $450 billion.